IA
NRIX icon

IFP Advisors’s Nurix Therapeutics NRIX Stock Holding History

IFP Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.43K Buy
+224
New +$3.82K ﹤0.01% 3741
2025
Q2 		– Hold
0
– – – 4502
2025
Q1 		– Sell
-6
Closed -$113 – 4537
2024
Q4 		$113 Buy
+6
New +$138 ﹤0.01% 3983

Other funds holding NRIX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

IFP Advisors's NRIX Position: Q2 2026 in Review

IFP Advisors opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 224 shares worth $5.43K. The stake represents ﹤0.01% of the portfolio and ranks #3741 among its holdings. This is a return to the name: IFP Advisors previously reported a position in NRIX as recently as Q4 2024.

IFP Advisors first reported a position in NRIX in Q4 2024 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • IFP Advisors held 224 shares of Nurix Therapeutics worth $5.43K as of Q2 2026.
  • Nurix Therapeutics was a new IFP Advisors position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3741 holding.
  • IFP Advisors first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.